Dupixent® considerably cut down on COPD flare-ups in its subsequent effective Phase 3 investigation, hastening its FDA application and affirming its potential as the initial sanctioned biologic treatment for this severe illness.

Sosei Heptares will reclaim complete ownership of GSK4381406*, a ready-for-clinic, unique oral GPR35 stimulant meant for inflamed bowel disorder.

Innovent makes announcement: China's National Medical Products Administration has permitted and given precedence in reviewing the new drug application, IBI351 - the first KRAS G12C inhibitor from the country.

Acrotech Biopharma and Evive Biotech have successfully received FDA authorization to use Ryzneuta® (Efbemalenograstim alfa injection) for treating Neutropenia caused by Chemotherapy (CIN).

EirGenix Inc. has delivered news regarding the receipt of a marketing endorsement from the European Commission for their trastuzumab biosimilar medication (EG12014).

Vertex Pharmaceuticals has announced that the European Commission has approved an expanded label for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in combination with ivacaftor to treat cystic fibrosis in children aged 2 to 5 with at least one F508del mutation in the CFTR gene.

Recently, Shanghai MicuRx Pharmaceuticals Co., Ltd. revealed that the first volunteer has been enlisted for the initial Phase I clinical examination of its innovative antibiotic MRX-5 in Australia.

Origen Chengdu and Vanotech have declared the first patient has received their gene therapy in the Phase 1 trial of VAN-2201 for Wet Macular Degeneration associated with aging.

At the 2023 SNO Annual Conference, Imvax displayed novel findings advocating for its principal project, IGV-001, targeting recently identified Glioblastoma.

HOOKIPA Pharma Inc. has officially disclosed that the FDA has given the clearance for its IND application for HB-500, This is a new arenaviral therapeutic vaccine designed for HIV treatment.

Sandoz announces the launch of its citrate-free high concentration Hyrimoz® (adalimumab) in Europe, with availability starting today in various countries.

European Commission gives the green light to Ascendis Pharma's YORVIPATH® (palopegteriparatide) for managing chronic Hypoparathyroidism in adults.